Introduction
============

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) occurs in 5% to 10% of hospitalized patients and is the leading cause of intrahospital mortality after AMI \[[@B1],[@B2]\]. Early revascularization of the infarct-related artery is the fundamental step in therapeutic strategies and has been shown to improve long-term survival in patients with CS \[[@B3],[@B4]\]. However, some patients fail to show clinical and hemodynamic improvement, with a poor prognosis despite successful immediate revascularization.

In the classic pathophysiologic view, CS is the result of temporary and permanent disorders in the circulatory system \[[@B5]\]. New irreversible injury, reversible ischemia, and damage from prior infarction contribute to left ventricular dysfunction. N-terminal-pro-B-type natriuretic peptide (Nt-proBNP) is used for the early diagnosis of heart failure (HF) in patients with acute dyspnea \[[@B6]\]. In patients with chronic HF and AMI, Nt-proBNP is a reliable predictor of increased mortality \[[@B7]\]. In addition, elevated BNP levels in patients with septic shock are indicative of septic cardiomyopathy \[[@B8]\].

Systemic inflammation with inappropriate vasodilatation, as evidenced by a normal to low range of systemic vascular resistance, is observed in many patients with CS and may contribute to an excess mortality rate \[[@B9]\]. Accordingly, it has been postulated that CS causes a systemic inflammatory response syndrome (SIRS) by the release of pro-inflammatory mediators like interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) \[[@B5]\]. Signs of systemic inflammation such as fever, leukocytosis, and elevated acute-phase reactants are frequently observed in patients with AMI and CS. High levels of systemic inflammation seem to be associated with impaired survival despite early revascularization \[[@B5]\]. It has been shown that patients with CS and multiorgan failure (MOF) exhibit concentrations of IL-6 of the same magnitude as do patients with septic shock \[[@B10],[@B11]\].

Procalcitonin (PCT) is a well-established biomarker for the diagnosis of sepsis \[[@B12]\]. PCT reflects the severity of bacterial infection and is used to monitor progression of infection into sepsis, severe sepsis, or septic shock. Moreover, PCT is used to measure the activity of the systemic inflammatory response \[[@B12]\]. The increase of PCT in patients with sepsis correlates with mortality \[[@B12]\]. A limited number of studies have reported that increased levels of PCT are related to AMI \[[@B13],[@B14]\].

In the present study, we analyzed the relation between plasma levels of Nt-proBNP, IL-6, and PCT at different points in time early after admission and 30-day mortality in patients with CS due to AMI, treated with immediate revascularization and IABP support. Moreover, central determinants of organ failure, hemodynamics, and revascularization were analyzed in relation to short-term prognosis and to levels of Nt-proBNP, IL-6, and PCT.

Materials and methods
=====================

Subjects
--------

The present study is a prospective observational single-center study at a university hospital. Between 2008 and 2010, 87 patients with AMI complicated by CS at admission were included. The study complies with the Declaration of Helsinki and was approved by the local medical ethics committee. Patients or, in case of unconsciousness, relatives signed a consent form. Underlying causes of CS were categorized as ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). CS was defined by the presence of one of the following criteria: (a) peak systolic pressure \<90 mm Hg for \>30 minutes after the correction of hypovolemia, hypoxemia, and acidosis or need for vasopressor and/or inotropic therapy; (b) signs of organ hypoperfusion such as oliguria/anuria, changes in mental state, or elevated serum lactate concentrations (\>2.0 m*M*). Patients with ongoing cardiopulmonary resuscitation (CPR) at admission were excluded from the study. Further exclusion criteria were age \<18 years, immunosuppressive therapy, preexisting infectious diseases, mechanical assist devices other than an intraaortic balloon counterpulsation (IABP), mechanical cardiac complications, and coronary artery bypass grafting (CABG) or any surgery in the last 4 weeks before onset of shock.

All patients were taken directly to the cardiac catheterization laboratory for angiography. All patients had undergone implantation of an IABP (Datascope System CS100 and CS100i, Datascope, Oakland, NJ, USA).

Based on the primary outcome variable all-cause mortality at day 30, analyses were performed to identify differences between survivors and nonsurvivors and predictors of worse outcome.

Hemodynamic measurements
------------------------

Stroke volume (SV) and left ventricular ejection fraction (EF) were quantified invasively with levocardiography. If levocardiography could not be performed, EF was quantified with echocardiography. Cardiac output (CO) (L/min) was calculated as SV × heart rate. Cardiac power output (CPO) (W) was calculated as mean arterial pressure (MAP) × CO/451, left ventricular work (LVW) as (MAP - left ventricular end-diastolic pressure (LVEDP)) × CO × 0.0136 (kg-m/min), and systemic vascular resistance (SVR) (dyne s/cm^5^) as 80 × (MAP - central venous pressure (CVP))/CO. Left ventricular work index (LVWI) (kg-m/min × m²), cardiac power index (CPI) (W/m²), and systemic vascular resistance index (SVRI) (dyne s/cm^5^/m²) were computed by substituting CO with CI in the respective formulas. Stroke work (SW) (g-m) was calculated as (MAP - LVEDP) × 0.0136 × SV. Stroke work index (SWI) (g-m/m²) was determined by SW/body surface area. Microcirculatory power index (micPI) was calculated as CI × (MAP-CVP) × Hkt-factor.

Blood sampling
--------------

The first blood sample (T~0~) was taken immediately after admission. The second blood sample (T~1~) was taken after 24 hours, and the third blood sample (T~2~), after 72 hours. Nt-proBNP (Siemens Healthcare Diagnostics GmbH, Munich, Germany), IL-6 (Siemens Healthcare Diagnostics GmbH) and PCT (Roche Diagnostics GmbH, Mannheim, Germany) were measured immediately. Further routine laboratory parameters were quantified by using commercially available assays.

Organ failure
-------------

Acute renal failure was defined as an increase of the serum creatinine concentration \>2.5 mg/dl, an increase in creatinine \>25% from baseline, a diuresis \<500 ml/24 hours, or need for hemofiltration. Estimated glomerular filtration rate (eGFR) was calculated by using the Cockroft and Gault formula. Systemic inflammatory response syndrome (SIRS) was defined by approved criteria \[[@B5]\]. Multiorgan failure (MOF) was defined as presence of two or more organ failures, other than cardiovascular. As scoring system of ICU mortality the APACHE II score was used.

Statistical analysis
--------------------

Continuous variables are expressed as mean [+]{.ul}standard deviation (SD) if normally distributed and as median (interquartile range) if not normally distributed. Continuous variables were tested for normal distribution with the use of the Kolmogorov-Smirnov test. The Student *t*test was performed for normally distributed continuous variables, and the Mann-Whitney *U*test for nonnormally distributed continuous variables. Testing for homogeneity of variance was performed with the Levene test. Categoric variables are given as frequencies and percentages, and the χ^2^test with the Fisher Exact test was used for data analysis. Receiver operating characteristics (ROC) curves were performed to determine cut-off levels of Nt-proBNP, IL-6, and PCT, with the highest sensitivity and specificity predicting 30-day mortality. The cumulative survival plots were estimated with the Kaplan-Meier method. Survival in groups was compared with the log-rank test. Univariate Cox regression analysis was performed to identify significant independent predictors of outcome.

For multivariate analysis, age, CPI, mean dose of catecholamines, lactate, creatinine, and IL-6 or PCT were included. For this analysis, a backward stepwise selection method was used. Results are reported as adjusted hazard ratio (HR) with 95% confidence interval (CI). A two-sided *P*value less 0.05 was considered statistically significant. Statistical analyses were performed by using SPSS software version 18.0 (SPSS, Chicago, IL, USA).

Results
=======

Primary end point 30-day mortality
----------------------------------

The overall 30-day mortality was 32.2% (*n*= 28 nonsurvivors, *n*= 59 survivors). No patient died in the catheterization laboratory. Six patients died before T~1~, and six further patients died before T~2~. Main cause of death was MOF. Mortalities showed no significant differences in STEMI versus NSTEMI patients, male versus female patients, or patients older than 75 years versus 75 years or younger (data not shown).

Baseline patient characteristics
--------------------------------

Baseline patient characteristics of survivors and nonsurvivors are shown in Table [1](#T1){ref-type="table"}. Age, percentage of patients receiving mechanical ventilation, serum lactate levels, hemoglobin, and serum creatinine differed significantly between the nonsurvivor and survivor groups. There were no further differences concerning patient characteristics and demographic data.

###### 

Baseline characteristics of study population according to outcome

                                            All patients(*n*= 87)   Survivors(*n*= 59)   Nonsurvivors(*n*= 28)   *P*value
  ----------------------------------------- ----------------------- -------------------- ----------------------- ----------
  Age (years)                               67.78 ± 13.4            64.68 ± 14.3         74.32 ± 8.4             \<0.0001
  Age \>75 years (%)                        35 (40.2)               19 (32.2)            14 (50.0)               0.156
  Male (%)                                  68 (78.2)               46 (78.0)            22 (78.6)               0.949
  STEMI/NSTEMI (%)                          44/43 (50.6/49.4)       30/29 (50.8/49.2)    14/14 (50.0/50.0)       0.941
  Diabetes (%)                              29 (33.3)               21 (35.6)            8 (28.6)                0.629
  Hypertension (%)                          53 (60.9)               37 (62.7)            16 (57.1)               0.645
  Dyslipidemia (%)                          43 (49.4)               31 (52.5)            12 (42.9)               0.493
  Smoker (%)                                31 (35.6)               23 (39.0)            8 (28.6)                0.473
  Obesity (%)                               20 (23.0)               15 (25.4)            5 (17.9)                0.587
  BMI (kg/m^2^)                             27.6 ± 5.5              27.7 ± 5.8           27.2 ± 4.8              0.739
  Family history (%)                        11 (12.6)               7 (11.9)             4 (14.3)                0.741
  CAD (%)                                   42 (48.3)               28 (47.5)            14 (50.0)               0.825
  Previous MI (%)                           25 (28.7)               17 (28.8)            8 (28.6)                0.981
  Previous PCI (%)                          24 (27.6)               17 (28.8)            7 (25.0)                0.801
  Previous CABG (%)                         6 (6.9)                 4 (6.8)              2 (7.1)                 0.950
  Chronic heart failure (%)                 11 (12.6)               8 (13.6)             3 (10.7)                0.978
  Previous stroke (%)                       10 (11.5)               8 (13.6)             2 (7.1)                 0.490
  Chronic renal failure (%)                 10 (11.5)               5 (8.5)              5 (17.9)                0.281
  Mechanical ventilation at admission (%)   43 (49.4)               28 (47.5)            15 (53.6)               0.651
  Mechanical ventilation at any time (%)    62 (71.3)               36 (61.0)            26 (91.3)               0.013
  Transferred patients (%)                  39 (44.8)               29 (49.2)            10 (35.7)               0.259
  Preclinical CPR (%)                       23 (26.4)               16 (27.1)            7 (25.0)                0.834
  Serum creatinine (mg/dl)                  1.44 (1.17/2.10)        1.34 (1.09/1.58)     1.99 (1.45/3.45)        \<0.0001
  Hemoglobin (g/dl)                         12.5 (10.5/14.4)        13.1 (11.1/14.9)     10.8 (10.0/13.5)        0.034
  Troponin I (ng/ml)                        14.7 (2.9/62.5)         9.1 (1.9/54.4)       21.0 (9.0/77.0)         0.069
  Blood glucose (mg/dl)                     199.0 ± 129.9           201.3 ± 142.1        193.3 ± 96.5            0.942
  Serum lactate (m*M*)                      1.9 (1.1/6.0)           1.4 (1.1/3.2)        5.8 (1.6/12.7)          0.008

Values are expressed as *n*(%), or mean ± SD. BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CPR, cardiopulmonary resuscitation; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

Diagnostic and therapeutic characteristics
------------------------------------------

All patients underwent coronary angiography immediately after admission. Diagnostic and therapeutic characteristics are summarized in Table [2](#T2){ref-type="table"}. Percutaneous coronary intervention (PCI) was performed technically successfully in 77 (96.3%) patients, defined by a patent vessel with TIMI [\>]{.ul}2 flow, \<50% residual stenosis, and no emergency CABG. Rates of successful PCI were similar in both groups (Table [2](#T2){ref-type="table"}). The most common reasons for not attempting revascularization/surgery were a high-risk operation due to low ejection fraction, irreversible MOF, and coronary vessels not suitable for PCI or CABG. Rate of periinterventional CPR was significantly elevated in the nonsurvivor group.

###### 

Procedural characteristics of study population according to outcome

                                                  All patients(*n*= 87)   Survivors(*n*= 59)   Nonsurvivors(*n*= 28)   *P*value
  ----------------------------------------------- ----------------------- -------------------- ----------------------- ----------
  EF (%)                                          35.2 ± 11.6             34.7 ± 11.6          36.4 ± 11.9             0.548
  EF \<30% (%)                                    24 (27.6)               16 (27.1)            9 (32.1)                0.789
  Three-vessel disease (%)                        51 (58.6)               34 (57.6)            17 (60.7)               0.814
  Infarct artery                                                                                                       
   Left main (%)                                  6 (6.9)                 4 (6.8)              2 (7.1)                 0.950
   Left anterior descending (%)                   43 (49.4)               29 (49.2)            14 (49.2)               0.941
   Right coronary artery (%)                      21 (24.1)               13 (22.0)            8 (28.6)                0.691
   Left circumflex (%)                            24 (27.6)               15 (25.4)            9 (32.1)                0.690
   Bypass graft (%)                               1 (1.1)                 1 (1.7)              0 (0)                   0.488
  Revascularization procedure (PCI or CABG) (%)   82 (94.3)               57 (96.6)            25 (89.3)               0.323
  PCI left main (%)                               12 (13.8)               10 (16.9)            2 (7.1)                 0.323
  PCI success (%)                                 77 (96.3)               55 (96.5)            22 (95.7)               0.858
  CABG (%)                                        2 (2.3)                 0 (0%)               2 (7.1)                 0.091
  Number of treated vessels                       1.26 ± 0.54             1.26 ± 0.48          1.25 ± 0.68             0.932
  Time to reperfusion (hours)                     6.1 ± 5.2               5.6 ± 4.6            7.3 ± 5.9               0.072
  Duration of IABP support (hours)                54.5 ± 24.0             55.4 ± 20.8          52.1 ± 31.3             0.654
  TIMI flow before PCI                            0.51 ± 0.67             0.51 ± 0.67          0.50 ± 0.71             0.958
  TIMI flow after PCI                             2.77 ± 0.57             2.82 ± 0.51          2.67 ± 0.70             0.343
  CPR periinterventional (%)                      12 (13.8)               5 (8.5)              7 (25.0)                0.040

Values are expressed as *n*(%), or mean ± SD. CABG, coronary artery bypass graft; CPR, cardiopulmonary resuscitation; EF, ejection fraction; IABP, intraaortic balloon counterpulsation; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.

Hemodynamic parameters and catecholamine support
------------------------------------------------

Values of hemodynamic measurements at admission are illustrated in Table [3](#T3){ref-type="table"}. For CPI, a significant difference was observed. In addition, MAP and systolic BP were reduced within the nonsurvivor group, whereas heart rate and maximal CVP within the first 24 hours were elevated in this group. Patients (68; 78.2%) required supportive catecholamine therapy within the first 24 hours, the more in the nonsurvivor group (Table [3](#T3){ref-type="table"}).

###### 

Hemodynamics and catecholamine support according to outcome

                                                     All patients(*n*= 87)   Survivors(*n*= 59)   Nonsurvivors(*n*= 28)   *P*value
  -------------------------------------------------- ----------------------- -------------------- ----------------------- ----------
  Hemodynamics                                                                                                            
  CI (L/min/m^2^)                                    2.15 ± 0.83             2.16 ± 0.78          2.12 ± 0.93             0.825
  CPI (W/m^2^)                                       0.35 ± 0.15             0.37 ± 0.15          0.30 ± 0.15             0.041
  CPO (W)                                            0.67 ± 0.26             0.70 ± 0.27          0.60 ± 0.25             0.102
  Microcirculatory PI                                97.51 ± 46.17           101.74 ± 43.08       86.23 ± 53.22           0.181
  SV (ml)                                            52.6 ± 16.5             54.7 ± 16.8          48.1 ± 15.4             0.078
  SVI (ml/m^2^)                                      26.8 ± 9.4              28.0 ± 9.0           24.3 ± 9.8              0.105
  SW (g m)                                           37.5 ± 18.5             39.4 ± 18.6          31.7 ± 17.5             0.121
  SWI (g m/m^2^)                                     19.1 ± 10.2             20.2 ± 10.1          16.0 ± 10.2             0.137
  LVW (kg m/min)                                     2.88 ± 1.35             2.97 ± 1.35          2.60 ± 1.37             0.327
  LVWI (kg m/min/m^2^)                               1.47 ± 0.77             1.53 ± 0.74          1.30 ± 0.84             0.320
  SVR (dynes sec/cm^5^)                              1,251.8 ± 672.9         1,285.3 ± 705.6      1,146.6 ± 566.9         0.444
  SVRI (dynes sec/cm^5^/m^2^)                        2,281.6 ± 898.2         2,302.9 ± 894.2      2,216.2 ± 938.8         0.756
  MAP (mm Hg)                                        71.1 ± 15.0             74.8 ± 13.7          63.8 ± 14.9             0.002
  Min. MAP (mm Hg) day 1                             55.1 ± 13.1             58.9 ± 10.9          45.8 ± 13.7             0.001
  Systolic BP (mm Hg)                                94.8 ± 22.7             98.6 ± 21.7          85.5 ± 23.0             0.036
  Min. systolic BP (mm Hg) day 1                     70.9 ± 17.7             75.8 ± 15.7          59.0 ± 16.8             0.001
  LVEDP (mm Hg)                                      23.1 ± 8.9              22.9 ± 9.3           23.7 ± 8.1              0.748
  CVP (mm Hg)                                        12.7 ± 5.8              12.2 ± 5.0           13.8 ± 7.6              0.416
  Max. CVP (mm Hg) day 1                             19.0 ± 8.3              17.2 ± 7.4           23.9 ± 8.9              0.008
  HR (beats/min)                                     82.1 ± 21.2             78.7 ± 19.4          89.4 ± 23.2             0.043
  Min. HR (beats/min) day 1                          59.0 ± 17.3             56.4 ± 13.7          65.5 ± 23.3             0.115
  Max. HR (beats/m) day 1                            123.2 ± 25.3            118.8 ± 23.8         134.0 ± 26.2            0.032
  Scvo~2~(%)                                         66.3 ± 16.9             67.6 ± 16.5          63.2 ± 18.0             0.378
  Min. Scvo~2~(%) day 1                              56.3 ± 13.5             56.2 ± 12.4          56.7 ± 16.3             0.905
  Inotropic and vasopressor support                                                                                       
  Catecholamine use (%)                              68 (78.2%)              43 (72.9)            25 (89.3)               0.101
  Dobutamine use (%)                                 52 (59.8)               33 (55.9)            20 (71.4)               0.240
  Mean dose of dobutamine (µg/min) day 1             500 (0/975)             250 (0/700)          950 (0/1,075)           0.021
  Norepinephrine use (%)                             64 (73.6)               39 (66.1)            25 (89.3)               0.036
  Mean dose of nor-epinephrine (µg/min) day 1        10 (0/61)               3 (0/15)             100 (40/130)            \<0.0001
  Epinephrine use (%)                                25 (28.7)               8 (13.6)             18 (64.3)               \<0.0001
  Mean dose of epinephrine (µg/min) day 1            0 (0/0.5)               0 (0/0)              15 (0/80)               \<0.0001
  Total number of catecholamines                     2.0 (1.0/2.0)           2.0 (0.0/2.0)        3.0 (2.0/3.0)           0.001
  Total mean dose of catecholamines (µg/min) day 1   503 (0.6/1013)          305 (0/706)          995 (165/1310)          0.006

Values are expressed as *n*(%), mean ± SD, or median with interquartile range (quartile 1 to quartile 3). Beats/min, beats per minute; BP, blood pressure; CI, cardiac index; CO, cardiac output; CPI, cardiac power index; CPO, cardiac power output; CVP, central venous pressure; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; LVW, left ventricular work; LVWI, left ventricular work index; MAP, mean arterial pressure; max, maximal; min, minimal; Scvo~2~, central venous oxygen saturation; SV, stroke volume; SVI, stroke volume index; SVR, systemic vascular resistance; SVRI, systemic ventricular resistance index; SW, stroke work; SWI, stroke work index.

Predictive value of Nt-proBNP, IL-6, and PCT for 30-day mortality
-----------------------------------------------------------------

Main purpose of the present study was to determine the predictive value of serial measurements of Nt-proBNP, IL-6, and PCT for 30-day mortality. Medians (interquartile ranges) in all patients accounted for Nt-proBNP, 4,065 (1,147/9,775) pg/ml at T~0~, 3,588 (1,667/7,376) pg/ml at T~1~, and 2,409 (1,082/5,235) pg/ml at T~2~; IL-6, 74.7 (18.1/255.5) pg/ml at T~0~, 46.5 (28.2/136.0) pg/ml at T~1~, and 26.8 (10.4/83.4) pg/ml at T~2~; PCT, 0.25 (0.10/1.40) µg/L at T~0~, 0.53 (0.10/1.68) µg/L at T~1~, and 0.43 (0.15/0.90) µg/L at T~2~. Significant differences between survivors and nonsurvivors were seen for Nt-proBNP at T~1~(2,831 versus 6,871 pg/ml; *P*= 0.024), for IL-6 at T~0~(30.7 versus 424.0 pg/ml; *P*\< 0.0001), and T~1~(41.9 versus 79.1 pg/ml; *P*= 0.015), and for PCT at T~1~(0.46 versus 2.42 µg/L; p = 0.001) and T~2~(0.32 versus 1.44 µg/L; *P*= 0.001) (Figure [1](#F1){ref-type="fig"}). In contrast, for CRP, no statistical differences were seen (data not shown).

![**Serial measurements of Nt-proBNP (a), interleukin-6 (IL-6) (b) and procalcitonin (PCT) (c) in survivors versus nonsurvivors at admission (T~0~), after 24 hours (T~1~), and after 72 hours (T~2~)**. In the box-and-whisker plot, the central box represents the interquartile range (IQR); the middle line represents the median. Outside values (○) are smaller/larger than the lower/upper quartile ± 1.5 × the IQR; far-out values (\*) are smaller/larger than the lower/upper quartile ± 3 × the IQR.](cc11467-1){#F1}

ROC curves calculated for Nt-proBNP, IL-6, and PCT at T~0~, T~1~, and T~2~are illustrated in Figure [2](#F2){ref-type="fig"}. At the earliest point in time, T~0~, only IL-6 was predictive of 30-day mortality; at T~1~, IL-6 and PCT showed significant *P*values, at T~2~PCT and Nt-proBNP were predictive of mortality. Comparing the area under the curve of the parameters at each point in time, the highest accuracy in predicting 30-day mortality was seen for IL-6 at T~0~, for PCT at T~1~, and for PCT at T~2~(Figure [2](#F2){ref-type="fig"}). Notably, the highest level of significance was found for IL-6 at T~0~. Based on these analyses, corresponding cut-off levels with highest sensitivity and specificity were calculated: T~0~IL-6, 307 pg/ml (sensitivity, 57.1%; specificity, 97.7%); T~1~PCT, 1.23 µg/L (sensitivity, 83.3%; specificity, 81.4%); T~2~PCT, 0.71 µg/L (sensitivity, 90.0%; specificity, 82.9%). Based on these cut-off levels, 30-day survival rates of patients according to Kaplan-Meier analyses differed highly significantly (Figure [3](#F3){ref-type="fig"}). Survival of patients with IL-6 levels below the cut-off value was significantly improved compared with that of patients with IL-6 levels above the cut-off value, irrespective of the presence of SIRS (*P*\< 0.05).

![**Receiver operating characteristic (ROC) curves for 30-day mortality**. Analysis of 30-day mortality calculated from values of Nt-proBNP, interleukin-6 (IL-6), and procalcitonin (PCT) at admission (T~0~) **(a)**, after 24 hours (T~1~) **(b)**, and after 72 hours (T~2~) **(c)**. ROC curve analysis with area under the curve and significance levels.](cc11467-2){#F2}

![**Kaplan-Meier survival curves according to cut-off levels of interleukin-6 (IL-6) (a) and procalcitonin (PCT) (b, c)**. Estimated 30-day survival in patients with levels of IL-6 above or below the cut-off level (307 pg/ml) at admission (T~0~) (a); of PCT (1.23 µg/L) after 24 hours (T~1~) (b); of PCT (0.71 µg/L) after 72 hours (T~2~) (c). *P*values were estimated by log-rank test.](cc11467-3){#F3}

Organ failure as predictor of 30-day mortality
----------------------------------------------

Acute kidney injury (AKI) occurred in 31 (35.6%) patients. AKI appeared significantly more frequent in nonsurvivors (67.9%) compared with survivors (20.7%; *P*\< 0.0001). Serum creatinine at admission (1.99 (1.45/3.45) mg/dl versus 1.34 (1.09/1.58) mg/dl) and eGFR (38.2 ± 19.4 ml/min versus 67.7 ± 31.5 ml/min) after the first 24 hours also differed significantly between the groups (*P*\< 0.0001). The incidence of MOF was increased dramatically in the nonsurvivor group (60.7% versus 6.8%; *P*\< 0.0001). According to Kaplan-Meier analyses, the overall 30-day survival rate of patients with MOF was markedly lower than that of patients without MOF (15.0% versus 84.8%; *P*\< 0.0001 by log-rank test). The overall survival rate of patients with an APACHE II score above the median was in trend lower than that of patients below this cutoff (62.9% versus 81.8%; *P*= 0.065). Initial serum lactate as a marker for organ hypoperfusion was clearly elevated within the nonsurvivor group (5.8 (1.6/12.7) m*M*versus 1.4 (1.1/3.2) m*M*; *P*\< 0.01).

Univariate and multivariate analyses of predictors for 30-day mortality
-----------------------------------------------------------------------

In univariate analysis, significant values were found for Nt-proBNP at T~1~, for IL-6 at all points in time, and for PCT also at all points in time (Table [4](#T4){ref-type="table"}). Further significant predictors are shown in Table [4](#T4){ref-type="table"}. Within the multivariate analysis including age, CPI at admission, total mean dose of catecholamines within first 24 hours, lactate at admission, creatinine at admission, IL-6 at admission, and PCT at admission, age, creatinine, and IL-6 were significant determinants of 30-day mortality in which IL-6 showed the highest level of significance (Table [5](#T5){ref-type="table"}).

###### 

Univariate analysis predicting 30-day mortality

                                           HR (95% CI)            *P*value
  ---------------------------------------- ---------------------- ----------
  Patient characteristics                                         
  Age, per 10 years                        1.638 (1.174-2.285)    0.004
  EF, per 5%                               1.061 (0.887-1.269)    0.516
  Left main                                2.143 (0.504-9.117)    0.302
  STEMI                                    1.005 (0.479-2.108)    0.989
  Mechanical ventilation                   1.313 (0.625-2.762)    0.472
  Hemodynamics and catecholamines                                 
  CO, L/min                                0.986 (0.760-1.279)    0.915
  CI, L/min/m^2^                           0.934 (0.594-1.468)    0.768
  CPI, 0.1 W/m^2^                          0.766 (0.593-0.991)    0.043
  CPO, 0.1 W                               0.874 (0.747-1.023)    0.094
  Microcirculatory PI/10                   0.888 (0.795-0.992)    0.036
  SVRI, 100 dynes sec/cm^5^/m^2^           0.992 (0.937-1.050)    0.776
  MAP, 5 mm Hg                             0.821 (90.726-0.928)   0.002
  Heart rate, 5 beats/min                  1.086 (1.003-1.176)    0.041
  Catecholamine use                        3.073 (0.716-13.198)   0.131
  Total number of catecholamines           2.332 (1.350-4.029)    0.002
  Mean dose of catecholamines, 10 µg/min   1.014 (1.004-1.024)    0.006
  Organ failure                                                   
  Acute kidney injury                      5.084 (2.290-11.290)   \<0.0001
  SIRS                                     1,412 (0.639-3.121)    0.394
  MOF                                      8.317 (3.754-18.425)   \<0.0001
  Lactate, m*M*                            1.164 (1.086-1.247)    \<0.0001
  APACHE II \> Median                      2.390 (0.908-6.294)    0.078
  Laboratory measurements                                         
  Creatinine T~0~, mg/dl                   1.299 (1.092-1.546)    0.003
  Creatinine T~1~, mg/dl                   2.155 (1.534-3.028)    \<0.0001
  Creatinine T~2~, mg/dl                   1.562 (0.626-3.901)    0.339
  Nt-proBNP T~0~, 1,000 pg/ml              1.022 (0.988-1.056)    0.204
  Nt-proBNP T~1~, 1,000 pg/ml              1.111 (1.045-1.182)    0.001
  Nt-proBNP T~2~, 1,000 pg/ml              1.109 (0.959-1.282)    0.161
  IL-6 T~0~, 100 pg/ml                     1.019 (1.008/1.030)    0.001
  IL-6 T~1~, 100 pg/ml                     1.134 (1.023-1.257)    0.016
  Il-6 T~2~, 100 pg/ml                     1.550 (1.031-2.331)    0.035
  PCT T~0~, µg/L                           1.368 (1.075-1.741)    0.011
  PCT T~1~, µg/L                           1.266 (1.122-1.429)    \<0.0001
  PCT T~2~, µg/L                           2.980 (1.687-5.265)    \<0.0001

IL-6, interleukin-6; MOF, multiorgan failure; Nt-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin; SIRS, systemic inflammatory response syndrome; other abbreviations as in Tables 1 through 3.

###### 

Multivariate Cox proportional hazard ratios for 30-day mortality

  -------------------------------------------------------------------
                                  Hazard ratios (95% CI)   *P*value
  ------------------------------- ------------------------ ----------
  Age, per 10 years               3.372 (1.548-7.348)      0.002

  CPI, 0.1 W/m^2^                 0.790 (0.506-1.231)      0.297

  Mean dose of catecholamines,\   1.013 (0.997-1.028)      0.116
  10 µg/min                                                

  Lactate T~0~, m*M*              1.007 (0.839-1.209)      0.939

  Creatinine T~0~, mg/dl          1.589 (1.033-2.444)      0.035

  IL-6 T~0~, 100 pg/ml            1.036 (1.017-1.055)      \<0.0001

  PCT T~0~, µg/L                  1.236 (0.843-1.812)      0.277
  -------------------------------------------------------------------

Abbreviations as in Tables 1 through 4.

Discussion
==========

The aim of the present study was to analyze the predictive value of a broad spectrum of clinical and laboratory parameters in patients with CS due to AMI treated with immediate revascularization. To the best of our knowledge, this is the first prospective investigation in the early phase of AMI and CS analyzing serial measurements of Nt-proBNP, IL-6, and PCT as predictors of 30-day mortality.

Growing evidence indicates that an aggressive strategy based on immediate coronary revascularization and IABP support is the most effective therapy for CS due to AMI \[[@B2],[@B5]\]. Characteristics of our study population were similar to those of the patients undergoing revascularization in the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial \[[@B15]\]. The present study was based on a therapy strategy that included urgent revascularization and support by an IABP. In contrast to the SHOCK trial, the predominant proportion of patients was revascularized by PCI with a high success rate and revealed a 30-day mortality of 32%, an incidence lower than that reported in the SHOCK trial \[[@B15]\].

Nt-proBNP, IL-6, and PCT as predictors of outcome
-------------------------------------------------

The measurement of serum levels of natriuretic peptides is established in the diagnosis and follow-up of chronic HF. Maisel *et al*. \[[@B6]\] showed that BNP may be helpful in diagnosing acute HF in the emergency setting. Moreover, Nt-proBNP has been suggested as a useful marker of high risk in acute myocardial infarction. Higher baseline levels of BNP in patients presenting with STEMI were associated with impairment of reperfusion after fibrinolytic therapy, whereas patients in the highest BNP-concentration quartile had an 11-fold risk of dying by 30 days \[[@B16]\]. Similarly, Nt-proBNP was previously shown to be predictive of myocardial damage, development of CS, and short- and long-term mortality \[[@B17],[@B18]\]. Data concerning the predictive value of serial Nt-proBNP measurements in patients with manifest CS due to AMI are rare. In the present study, the survivor group showed a decline of Nt-proBNP levels within 72 hours, whereas in the nonsurvivor group, maximum levels were reached after 24 hours. Significant differences of Nt-proBNP were found only after 24 hours between survivors and nonsurvivors. Notably, Nt-proBNP revealed no predictive value for the development of MOF. In a retrospective study with 58 patients with CS largely secondary to AMI, initial Nt-proBNP levels above the median were associated with worsened outcome \[[@B19]\]. However, Nt-proBNP levels were not analyzed serially. Next to the retrospective study design, the number of patients was small in particular if the cohort was further subdivided. Among the 47 patients who had AMI as the primary cause of CS, only in 33 patients was coronary revascularization performed, with a success rate of 85% \[[@B19]\]. In our study, revascularization was attempted in 94% of patients, with a success rate of 96%, and an IABP was placed in all patients.

In patients with septic shock, IL-6 levels have been shown to correlate with disease severity and outcome \[[@B20]\]. However, elevations are not sepsis specific. It has been shown that patients with CS and manifest MOF exhibit similarly high IL-6 levels, as in patients with septic shock \[[@B10]\]. In the setting of AMI, IL-6 was identified as independent prognostic marker \[[@B21]\]. In the present study, IL-6 levels differed significantly between the survivor and nonsurvivor groups at the early points in time, in which the values at admission showed an impressive discrepancy. In accordance with that, univariate analysis confirmed the predictive value of IL-6 for 30-day mortality at the early points in time. IL-6 levels at admission revealed the highest level of significance within the ROC analyses. A cut-off level of 307 pg/ml showed a very clear differentiation between survivors and nonsurvivors within the Kaplan-Meier curves, associated with a very high specificity of 98%. Moreover, in contrast to Nt-proBNP, IL-6 levels at T~0~and T~1~were predictive for occurrence of MOF. Our data confirm the results of a small retrospective study with only initial measurements of IL-6 that also showed an independent predictive value of IL-6 for 30-day mortality \[[@B11]\]. It is hypothesized that next to ischemic myocardium, whole body ischemia, endotoxin translocation from the gut, excessive vasopressor therapy, and noncardiac organ failure are also contributing factors to IL-6 release \[[@B22]\]. Possibly, IL-6 constitutes not only an innocent bystander of inflammatory activation, but also might be an aggravating factor because IL-6 determines negative inotropic effects on the myocardium \[[@B23]\].

Several studies have demonstrated that elevated levels of PCT indicate bacterial infection accompanied by a systemic inflammatory reaction \[[@B12]\]. Nevertheless, PCT elevation has been documented in infection-independent systemic inflammatory reactions. In recent studies, PCT levels were found to correlate with the extent of coronary artery disease and adverse outcome \[[@B24]\]. In a retrospective study, CS patients showed high PCT concentrations, especially in the presence of MOF and in the absence of signs of infection \[[@B25]\]. In a further investigation, PCT values were significantly higher in CS patients compared with patients with uncomplicated AMI \[[@B26]\]. The prognostic relevance of PCT in CS was not evaluated. In our study, both survivors and nonsurvivors reached maximum levels of PCT at T~1~. Significant differences between the two groups were seen at T~1~and T~2~and were strongly associated with outcome. ROC analysis showed the highest accuracy of predicting 30-day mortality for PCT at T~1~and T~2~with a sensitivity and specificity between 80% and 90%. Notably, when comparing the area under the curve of Nt-proBNP, IL-6, and PCT, at all points in time, PCT at T~1~showed the highest value.

Hemodynamics and organ failure as predictors of outcome
-------------------------------------------------------

Hemodynamic data, including CO and pulmonary wedge pressure, were shown to be the strongest predictors of death in the GUSTO CS trial \[[@B27]\]. In a retrospective analysis from the SHOCK trial registry, CPI was the strongest predictor of mortality \[[@B28]\]. In our study, hemodynamic measurements also showed a predictive value of CPI in the univariate but not multivariate analysis.

Impaired renal function is one of the strongest risk factors for cardiovascular mortality. In a retrospective analysis in patients with CS due to AMI, 33% developed an AKI within 24 hours of shock onset and showed a significantly higher mortality rate than did patients without AKI \[[@B29]\]. In a recent prospective study of STEMI patients with CS, AKI occurred in 55% of patients, and the in-hospital mortality rate was significantly higher in patients developing AKI than in patients without AKI \[[@B30]\]. In our study with STEMI and also NSTEMI patients, AKI occurred in 36% of patients during first 72 hours after admission. All measured parameters of renal insufficiency were clearly associated with worse outcome.

Irreversible MOF is the main cause of death in CS. Until now, only a few studies addressed the issue of MOF in patients with CS. In a small study, 35% of patients with CS exhibited MOF at admission categorized by the SOFA score, and an additional 20% developed MOF later during the clinical stay \[[@B10]\]. In our study, 24% of patients fulfilled criteria of MOF with a highly significant difference to the disadvantage of nonsurvivors.

IL-6 is the strongest independent predictor of 30-day mortality
---------------------------------------------------------------

As the central finding of our study, multivariate analysis including age, creatinine, lactate, CPI, mean dose of catecholamines, and IL-6 or PCT showed independent predictive values for age, creatinine, and IL-6, in which IL-6 reached the highest level of significance. Therefore, IL-6 might be a useful marker to identify very early CS patients who are at high risk of worse outcome. In contrast, the relevance of Nt-proBNP as an early prognostic marker must be challenged. PCT showed also a highly significant impact but primarily after the very early phase of AMI and CS.

Conclusions
===========

The present study demonstrates that in patients with AMI and CS treated with immediate revascularization and IABP, the destination of IL-6 at admission reliably predicts 30-day mortality. For clinical practice, it is noticeable that a cut-off level of 307 pg/ml is associated with a very high specificity but moderate sensitivity. In contrast, Nt-proBNP seemed to be of lower relevance.

In conclusion, selective measurements of circulating inflammatory markers allow early prognostic estimation of patients with CS due to AMI. Potential therapeutic and prognostic interventions modulating the systemic inflammatory reaction have to be analyzed in further studies.

Key messages
============

• Systemic inflammation is observed in many patients with cardiogenic shock due to myocardial infarction.

• Interleukin-6 represents a reliable independent very early prognostic marker of 30-day mortality with high specificity.

• Procalcitonin is a very reliable predictor of 30-day mortality 24 and 72 hours after admission, with high sensitivity and specificity.

Abbreviations
=============

AMI: acute myocardial infarction; CABG: coronary artery bypass graft; CPR: cardiopulmonary resuscitation; CS: cardiogenic shock; IL-6: interleukin-6; MOF: multiorgan failure; NSTEMI: non-ST-elevation myocardial infarction; Nt-proBNP: N-terminal pro-B-type natriuretic peptide; PCI: percutaneous coronary intervention; PCT: procalcitonin; SIRS: systemic inflammatory response syndrome; STEMI: ST-elevation myocardial infarction.

Competing interests
===================

The authors declare that they have no competing interests.

Authors\' contributions
=======================

RPA, UMB, GN, and JOS participated in the conception and design or analysis and interpretation of data. RPA, UMB, RF, VT, JWS, GN, and JOS drafted the manuscript or revised it critically for important intellectual content. RPA, UMB, GN, and JOS gave final approval of the manuscript. All authors read and approved the manuscript for publication.
